April 10, 2020: The Week in Cancer News
Young adults with a history of cancer are more likely to try e-cigarettes than their peers, and more news of the week from Cancer Today.
Progress Against Cancer
Young adults with a history of cancer are more likely to try e-cigarettes than their peers, and more news of the week from Cancer Today.
The first allogeneic hematopoietic-cell transplant (HCT) – a complex procedure where a patient receives blood stem cells isolated from a healthy donor – was performed in 1957. Now, over 9,000 allogeneic hematopoietic-cell transplants are performed per year in the United States. This type of transplant is generally used to treat patients with bone marrow disorders, including certain types of leukemia, lymphoma, and multiple myeloma.
CAR-T cell therapy may help patients after a relapse of mantle cell lymphoma, and more news of the week from Cancer Today.
The world is facing a pandemic unlike any in living memory. For our cancer research community, the novel coronavirus epidemic evokes memories of the 2003 outbreak of Severe Acute Respiratory Syndrome (SARS), which had far-reaching effects including the rescheduling of American Association for Cancer Research (AACR) Annual Meeting. Yet the total reported caseload of SARS was approximately 8,000, with 774 deaths; only 29 cases were identified in the United States.
Cancer centers are making changes to care for some patients enrolled in trials.
Pancreatic cancer remains a difficult disease to treat and is expected to be the second leading cause of U.S. cancer-related deaths by 2030.
A gene-editing tool called CRISPR holds promise for treating cancer. What does the new technology mean for patients?
The Cytosponge provides a cheaper alternative to an endoscopy.
The American Society for Radiation Oncology created guidelines to address controversies over when radiation should be used.
Typically, patients are treated with heparin, an injectable blood thinner, after a blood clot develops, but updated guidelines support use of oral blood thinners.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More